公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG ; Rimassa L. | Future Oncology | 50 | 49 | |
2018 | Cabozantinib in patients with advanced and progressing hepatocellular carcinoma | Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG ; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. | New England Journal of Medicine | 1553 | 1405 | |
2020 | Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma | Kelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG ; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K. | Advances in Therapy | 31 | 28 | |
2022 | Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade | Kelley R.K.; Miksad R.; Cicin I.; Chen Y.H.; Kl?mpen H.-J.; Kim S.; ZHONG-ZHE LIN ; Youkstetter J.; Hazra S.; Sen S.; ANN-LII CHENG ; El-Khoueiry A.B.; Meyer T.; Abou-Alfa G.K. | British Journal of Cancer | 17 | 14 | |
2019 | An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma | El Dika I.; Lim H.Y.; Yong W.P.; CHIA-CHI LIN ; Yoon J.-H.; Modiano M.; Freilich B.; Choi H.J.; Chao T.-Y.; Kelley R.K.; Brown J.; Knox J.; Ryoo B.-Y.; Yau T.; Abou-Alfa G.K. | Oncologist | 75 | 59 | |
2018 | Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma | Javle M.; Lowery M.; Shroff R.T.; Weiss K.H.; Springfeld C.; Borad M.J.; Ramanathan R.K.; Goyal L.; Sadeghi S.; Macarulla T.; El-Khoueiry A.; Kelley R.K.; Borbath I.; Choo S.P.; Oh D.-Y.; Philip P.A.; Chen L.-T.; Reungwetwattana T.; Van Cutsem E.; KUN-HUEI YEH ; Ciombor K.; Finn R.S.; Patel A.; Sen S.; Porter D.; Isaacs R.; Zhu A.X.; Abou-Alfa G.K.; Bekaii-Saab T. | Journal of Clinical Oncology | 511 | 428 | |
2020 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial | Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG ; Meyer T.; Abou-Alfa G.K. | ESMO open | 46 | 46 | |
2020 | Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma | Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG ; El-Khoueiry A.B.; Abou-Alfa G.K. | Clinical Cancer Research | 54 | 44 | |
2021 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma | Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG ; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I. | Journal for ImmunoTherapy of Cancer | 39 | 34 |